Americans Want Weight-Loss Pills for Cost and Convenience, Survey Finds

A Reuters/Ipsos survey published in early April 2026 found that 70% of Americans who want to lose weight would prefer a pill over an injection. The reasons are straightforward: pills are cheaper to manufacture, easier to store (no cold chain), and avoid the psychological barrier of self-injection.

Oral semaglutide (the Wegovy pill) is already being used by approximately 400,000 Americans roughly ten weeks post-launch, according to industry data. Many of these are first-time GLP-1 users who were reluctant to start injections. Eli Lilly’s oral orforglipron (Foundayo), which showed up to 9.2% weight loss in Phase 3 trials, is expected to file for FDA approval in late 2026.

The pill market could be enormous. Novo Nordisk and Eli Lilly both project that oral GLP-1s could eventually capture 30–40% of the total market, expanding access to people who were previously priced out or needle-averse. However, pills also have downsides: orforglipron showed higher rates of gastrointestinal side effects and discontinuation compared to oral semaglutide in head-to-head data.

Prices for oral options are expected to land in the $149–$349 per month range, significantly below injectable retail prices of $850–$1,350.

Frequently Asked Questions

Are oral GLP-1s as effective as injections?

Oral semaglutide produces weight loss comparable to the injectable form — typically 12–15% of body weight over 68 weeks. Orforglipron’s Phase 3 data showed 9.2% weight loss at the highest dose, which is slightly lower than semaglutide but still clinically meaningful.

Why are pills cheaper than injections?

Pills do not require the complex cold-chain logistics of biologic injections, and they are cheaper to manufacture at scale. Additionally, oral small-molecule drugs like orforglipron can be produced generically more easily than peptide-based injections.

Will insurance cover oral GLP-1s?

Coverage is still being negotiated. Some commercial plans already cover oral semaglutide with prior authorization. Medicare coverage for weight-loss medications is currently limited but under review, with a potential pilot program delayed indefinitely.

Source: Reuters